These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 17619828

  • 1. Thrombophilic mutations among Southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden.
    Rahimi Z, Vaisi-Raygani A, Nagel RL, Muniz A.
    J Thromb Thrombolysis; 2008 Jun; 25(3):288-92. PubMed ID: 17619828
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran.
    Rahimi Z, Vaisi-Raygani A, Mozafari H, Kharrazi H, Rezaei M, Nagel RL.
    J Thromb Thrombolysis; 2008 Jun; 25(3):280-3. PubMed ID: 17700999
    [Abstract] [Full Text] [Related]

  • 3. Factor V Leiden G1691A, Prothrombin G20210A, and MTHFR C677T and A1298C Mutations in Patients With Sickle Cell Disease in Tunisia.
    Belhaj Nefissi R, Doggui R, Ouali F, Messaoud T, Gritli N.
    Hemoglobin; 2018 Mar; 42(2):96-102. PubMed ID: 30200836
    [Abstract] [Full Text] [Related]

  • 4. Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India.
    Nishank SS, Singh MP, Yadav R.
    Eur J Haematol; 2013 Nov; 91(5):462-6. PubMed ID: 23992124
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cerebral venous and sinus thrombosis and thrombophilic mutations in Western Iran: association with factor V Leiden.
    Rahimi Z, Mozafari H, Bigvand AH, Doulabi RM, Vaisi-Raygani A, Afshari D, Razazian N, Rezaei M.
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):430-4. PubMed ID: 19703820
    [Abstract] [Full Text] [Related]

  • 8. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran.
    Rahimi Z, Nomani H, Mozafari H, Vaisi-Raygani A, Madani H, Malek-Khosravi S, Parsian A.
    Blood Coagul Fibrinolysis; 2009 Jun; 20(4):252-6. PubMed ID: 19349859
    [Abstract] [Full Text] [Related]

  • 9. Association between apolipoprotein ε4 allele, factor V Leiden, and plasma lipid and lipoprotein levels with sickle cell disease in Southern Iran.
    Rahimi Z, Vaisi-Raygani A, Pourmotabbed T.
    Mol Biol Rep; 2011 Feb; 38(2):703-10. PubMed ID: 20373031
    [Abstract] [Full Text] [Related]

  • 10. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.
    Lijfering WM, Middeldorp S, Veeger NJ, Hamulyák K, Prins MH, Büller HR, van der Meer J.
    Circulation; 2010 Apr 20; 121(15):1706-12. PubMed ID: 20368522
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J, Vayá A, Estellés A, Mira Y, Seguí R, Villa P, Ferrando F, Falcó C, Corella D, España F.
    Haematologica; 2000 Dec 20; 85(12):1271-6. PubMed ID: 11114134
    [Abstract] [Full Text] [Related]

  • 13. The clinical impact of MTHFR polymorphism on the vascular complications of sickle cell disease.
    Moreira Neto F, Lourenço DM, Noguti MA, Morelli VM, Gil IC, Beltrão AC, Figueiredo MS.
    Braz J Med Biol Res; 2006 Oct 20; 39(10):1291-5. PubMed ID: 16906320
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of factor V Leiden G1691A, MTHFR C677T, and prothrombin G20210A among Asian Indian sickle cell patients.
    Pandey SK, Meena A, Kishor K, Mishra RM, Pandey S, Saxena R.
    Clin Appl Thromb Hemost; 2012 Jun 20; 18(3):320-3. PubMed ID: 22084413
    [Abstract] [Full Text] [Related]

  • 15. The Contributions of Thrombophilic Mutations to Genetic Susceptibility to Deep Venous Thrombosis in Iraqi Patients.
    Al-Allawi NA, Badi AI, Goran MA, Nerweyi FF, Ballo HM, Al-Mzury NT.
    Genet Test Mol Biomarkers; 2015 Sep 20; 19(9):500-4. PubMed ID: 26196588
    [Abstract] [Full Text] [Related]

  • 16. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis.
    Almawi WY, Tamim H, Kreidy R, Timson G, Rahal E, Nabulsi M, Finan RR, Irani-Hakime N.
    J Thromb Thrombolysis; 2005 Jun 20; 19(3):189-96. PubMed ID: 16082606
    [Abstract] [Full Text] [Related]

  • 17. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL.
    Thromb Haemost; 2001 Sep 20; 86(3):809-16. PubMed ID: 11583312
    [Abstract] [Full Text] [Related]

  • 18. Factor V Leiden G1691A and prothrombin G20210A mutations among Palestinian patients with sickle cell disease.
    Samarah F, Srour MA.
    BMC Hematol; 2018 Sep 20; 18():1. PubMed ID: 29372059
    [Abstract] [Full Text] [Related]

  • 19. PLA2 polymorphism of platelet glycoprotein IIb/IIIa but not Factor V Leiden and prothrombin G20210A polymorphisms is associated with venous thromboembolism and more recurrent events in central Iran.
    Pourgheysari B, Boroujeni HR, Hasheminia AM, Drees F.
    Blood Coagul Fibrinolysis; 2013 Jul 20; 24(5):471-6. PubMed ID: 23358226
    [Abstract] [Full Text] [Related]

  • 20. Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A.
    Huber S, McMaster KJ, Voelkerding KV.
    J Mol Diagn; 2000 Aug 20; 2(3):153-7. PubMed ID: 11229520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.